^
Association details:
| Biomarker: | FLT3 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) |
| Drug Class: | Hypomethylating agent |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia
Excerpt:
...a documented FMS-like Tyrosine Kinase (FLT3) mutation in bone marrow or peripheral blood, as described in the protocol....
Trial ID:
Source:
Title:
Study aimed at evaluating the efficacy of the combination of the two drugs, Venetoclax and Azacitidine, on the treatment of patients suffering from Acute Myeloid Leukemia with NPM1 mutation. Studio volro a valutare l'efficacia della combinazione dei due farmaci, Venetoclax ed Azacitidina, sul trattamento di pazienti affetti da Leucemia Mieloide Acuta con mutazione di NPM1.
Excerpt:
...Pazienti che hanno ricevuto una precedente diagnosi di leucemia mieloide acuta con mutazione di NPM1 con o senza concomitante mutazione di FLT3-TKD o FLT3-ITD3. ...
Trial ID:
Less C2 evidence
Source:
Title:
996 Factors Associated with Clinical Outcomes after Venetoclax-Based Combination Therapy in Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
Published date:
11/04/2020
Excerpt:
Ven was given in combination with HMA, low dose cytarabine (LDAC), or IC in 35 (83.3%), 6 (14.3%), and 1 (2.4%) pt respectively....CR/CRi rates were higher for pts with FLT3 (p=.040) and NPM1 mutations (p=.04).
